Cargando…
Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains un...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485876/ https://www.ncbi.nlm.nih.gov/pubmed/36148458 http://dx.doi.org/10.3389/fmed.2022.915159 |
_version_ | 1784792155702689792 |
---|---|
author | Liu, Yahui Huang, Chunrong Du, Juan Lan, Gelei Du, Xueqing Sun, Yidan Shi, Guochao |
author_facet | Liu, Yahui Huang, Chunrong Du, Juan Lan, Gelei Du, Xueqing Sun, Yidan Shi, Guochao |
author_sort | Liu, Yahui |
collection | PubMed |
description | BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains unknown. METHODS: In order to explore the efficacy of AASs in patients with COPD, systematic search of MEDLINE, Embase, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials (RCTs) of AASs for COPD published before March 17, 2022 was performed. RESULTS: Data were extracted from 8 articles involving 520 participants. The median number of participants per study was 39.5 and the mean follow up was 14.2 weeks. As compared to the control group, AASs therapy could significantly improve body weight (weighted mean difference (WMD), 1.38 kg; 95% CI, 0.79 to 1.97 kg), fat-free mass (WMD, 1.56 kg; 95% CI, 0.94 to 2.18 kg) and peak workload (WMD, 6.89W; 95% CI, 3.97 to 9.81W) of COPD patients, but no improvements in spirometry indicators and six-minute walking distances (WMD, 16.88 m; 95%, −3.27 to 37.04 m). Based on the available research data, it is uncertain whether AASs treatment could improve the quality of life of COPD patients. CONCLUSIONS: Limited published evidence indicates that AASs therapy provides clinical benefits in patients with COPD. However, longer and larger studies are needed to better clarify the efficacy of AASs and draw final conclusions. |
format | Online Article Text |
id | pubmed-9485876 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94858762022-09-21 Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis Liu, Yahui Huang, Chunrong Du, Juan Lan, Gelei Du, Xueqing Sun, Yidan Shi, Guochao Front Med (Lausanne) Medicine BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains unknown. METHODS: In order to explore the efficacy of AASs in patients with COPD, systematic search of MEDLINE, Embase, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials (RCTs) of AASs for COPD published before March 17, 2022 was performed. RESULTS: Data were extracted from 8 articles involving 520 participants. The median number of participants per study was 39.5 and the mean follow up was 14.2 weeks. As compared to the control group, AASs therapy could significantly improve body weight (weighted mean difference (WMD), 1.38 kg; 95% CI, 0.79 to 1.97 kg), fat-free mass (WMD, 1.56 kg; 95% CI, 0.94 to 2.18 kg) and peak workload (WMD, 6.89W; 95% CI, 3.97 to 9.81W) of COPD patients, but no improvements in spirometry indicators and six-minute walking distances (WMD, 16.88 m; 95%, −3.27 to 37.04 m). Based on the available research data, it is uncertain whether AASs treatment could improve the quality of life of COPD patients. CONCLUSIONS: Limited published evidence indicates that AASs therapy provides clinical benefits in patients with COPD. However, longer and larger studies are needed to better clarify the efficacy of AASs and draw final conclusions. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485876/ /pubmed/36148458 http://dx.doi.org/10.3389/fmed.2022.915159 Text en Copyright © 2022 Liu, Huang, Du, Lan, Du, Sun and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Liu, Yahui Huang, Chunrong Du, Juan Lan, Gelei Du, Xueqing Sun, Yidan Shi, Guochao Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title | Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title_full | Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title_fullStr | Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title_full_unstemmed | Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title_short | Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis |
title_sort | anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485876/ https://www.ncbi.nlm.nih.gov/pubmed/36148458 http://dx.doi.org/10.3389/fmed.2022.915159 |
work_keys_str_mv | AT liuyahui anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT huangchunrong anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT dujuan anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT langelei anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT duxueqing anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT sunyidan anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis AT shiguochao anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis |